GlassScriptPhysician profile
Elnaz Malekahmadi
NPI 1114495710
$4,615.76
in general payments reported to CMS, 2019-2025
29 companies · $558 in 2025
The $558 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $634 · 2022: $1,019 · 2023: $1,081 · 2024: $1,324 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $862.31 | 2021-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $543.84 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $444.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $425.06 | 2021-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $366.03 | 2021-2024 | Velphoro, Korsuva |
| Opko Pharmaceuticals, LLC | $218.40 | 2022-2024 | Rayaldee |
| Novo Nordisk INC | $182.41 | 2024-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.98 | 2023-2025 | Jardiance |
| Amgen INC. | $177.17 | 2022-2025 | Tavneos, Parsabiv, Uplizna |
| Ardelyx, INC. | $169.84 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $144.09 | 2021-2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $127.78 | 2022-2024 | Tarpeyo |
| Amarin Pharma, INC. | $126.82 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $116.78 | 2023-2024 | |
| Apellis Pharmaceuticals, INC. | $86.15 | 2025 | Empaveli |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $68.02 | 2024-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $53.85 | 2024-2025 | Ultomiris |
| Daiichi Sankyo INC. | $50.25 | 2022 | |
| Viiv Healthcare Company | $43.18 | 2023 | Dovato |
| Genzyme Corporation | $30.83 | 2022 | |
| Shield Therapeutics INC | $29.44 | 2022 | |
| Idorsia Pharmaceuticals US INC | $28.93 | 2025 | Tryvio |
| Ultragenyx Pharmaceutical INC. | $24.92 | 2023 | Crysvita |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.19 | 2024 | Xifaxan |
| Glaxosmithkline, LLC. | $19.55 | 2023 | Benlysta |
| Janssen Pharmaceuticals, INC | $19.43 | 2024 | Xarelto |
| Arbor Pharmaceuticals, INC. | $19.22 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.15 | 2023 | Keveyis |
| Scpharmaceuticals INC. | $15.77 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elnaz Malekahmadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.